Research programme: urokinase inhibitors - Molecumetics
Latest Information Update: 04 Sep 2000
At a glance
- Originator Molecumetics
- Class Small molecules
- Mechanism of Action Urokinase-type plasminogen activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Sep 2000 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 17 Nov 1998 New profile
- 17 Nov 1998 Preclinical development for Cancer in USA (Unknown route)